Shionogi to acquire global rights to ALS drug RADICAVA in $700M-revenue deal
What's the deal? Japan-based Shionogi & Co. announced it will acquire the global rights to RADICAVA ORS (edaravone) and IV RADICAVA from Tanabe Pharma Corporation, both headquartered in Osaka. The deal involves Shionogi purchasing 100% of shares in a newly established entity that Tanabe Pharma will create to hold the RADICAVA business rights and assets.
As part of the transaction, a new US-based business company established by Tanabe for RADICAVA will become a wholly owned subsidiary of Shionogi Inc. The deal is expected to add approximately $700M in annual global sales and be immediately accretive in the fiscal year 2026.
Why now? Shionogi has been building a strategic focus in rare disease, with development programmes in Fragile X syndrome, Jordan's Syndrome, and Pompe disease. Acquiring RADICAVA gives it an established commercial platform and existing infrastructure — including patient and healthcare community relationships — to support those future launches.
RADICAVA ORS is approved by the US Food and Drug Administration (FDA) and other regulatory agencies worldwide for treating amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no cure and few treatment options. The drug has been used to treat more than 20,000 people with ALS in the US to date.
What could go wrong? ALS remains a small patient population, and the rare disease market is competitive. Shionogi will need to maintain the relationships Tanabe Pharma built with the ALS community while integrating the business — never a simple task in cross-company acquisitions.
The signal: The deal reflects a broader trend of pharmaceutical companies bolstering their rare disease portfolios through acquisition rather than internal development alone. For Shionogi, best known for its infectious disease expertise, this marks a deliberate pivot into a category where unmet medical needs — and pricing power — remain high. It also signals that established rare disease drugs with proven revenue streams continue to command premium valuations as platform assets.
Read more: shionogi.com
